Open AccessOral Administration of the Broad-Spectrum Antibiofilm Compound Toremifene Inhibits Candida albicans and Staphylococcus aureus Biofilm Formation In Vivo
Author(s) -
Kaat De Cremer,
Nicolas Delattin,
Katrijn De Brucker,
Annelies Peeters,
Soňa Kucharíková,
Evelien Gerits,
Natalie Verstraeten,
Jan Michiels,
Patrick Van Dijck,
Bruno P.A. Cammue,
Karin Thevissen
Publication year - 2014
Publication title -
antimicrobial agents and chemotherapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.07
H-Index - 259
eISSN - 1070-6283
pISSN - 0066-4804
DOI - 10.1128/aac.03869-14
Subject(s) - candida albicans , microbiology and biotechnology , candida krusei , candida glabrata , staphylococcus aureus , biofilm , staphylococcus epidermidis , pseudomonas aeruginosa , in vivo , candida dubliniensis , corpus albicans , chemistry , biology , bacteria , genetics
We here report on the in vitro activity of toremifene to inhibit biofilm formation of different fungal and bacterial pathogens, including Candida albicans, Candida glabrata, Candida dubliniensis, Candida krusei, Pseudomonas aeruginosa, Staphylococcus aureus, and Staphylococcus epidermidis. We validated the in vivo efficacy of orally administered toremifene against C. albicans and S. aureus biofilm formation in a rat subcutaneous catheter model. Combined, our results demonstrate the potential of toremifene as a broad-spectrum oral antibiofilm compound.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom